Association between Apolipoprotein B/Apolipoprotein A-1 and arterial stiffness in metabolic syndrome

Clinica Chimica Acta

Volumn 437, Issue , 2014, Pages 115-119

  Kim, Min Kyung ^a   Ahn, Chul Woo ^a   Kang, Shinae ^a   Ha, Ji Yoon ^a   Baek, Haeri ^a   Park, Jong Suk ^a   Kim, Kyung Rae ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Apolipoprotein A 1; Apolipoprotein B; Apolipoprotein B Apolipoprotein A 1 ratio; Arterial stiffness; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; APOLIPOPROTEIN B APOLIPOPROTEIN A 1 RATIO; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; HEALTH SURVEY; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PROCEDURES;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POPULATION SURVEILLANCE; VASCULAR STIFFNESS;

EID: 84907320481     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.07.005     Document Type: Article

References (43)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
3. Corsetti J.P., Zareba W., Moss A.J., Sparks C.E. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 2004, 177:367-373.
4. Rahmani M., Raiszadeh F., Allahverdian S., Kiaii S., Navab M., Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002, 162:381-389.
5. Cavalli S.A., Hirata M.H., Salazar L.A., et al. Apolipoprotein B gene polymorphisms: prevalence and impact on serum lipid concentrations in hypercholesterolemic individuals from Brazil. Clin Chim Acta 2000, 302:189-203.
6. Tian L., Wu X., Fu M., Qin Y., Xu Y., Jia L. Relationship between plasma apolipoproteinB concentrations, apolipoproteinB/apolipoproeinA-I and HDL subclasses distribution. Clin Chim Acta 2008, 388:148-155.
7. Liu C.S., Li C.I., Shih C.M., et al. Arterial stiffness measured as pulse wave velocity is highly correlated with coronary atherosclerosis in asymptomatic patients. J Atheroscler Thromb 2011, 18:652-658.
8. van Popele N.M., Grobbee D.E., Bots M.L., et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001, 32:454-460.
9. Yamashina A., Tomiyama H., Arai T., et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003, 26:615-622.
10. Cohn J.N. Arterial stiffness. J Hypertens 1999, 17:1227.
11. Mozumdar A., Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011, 34:216-219.
12. Nestel P., Lyu R., Low L.P., et al. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr 2007, 16:362-367.
13. Scuteri A., Laurent S., Cucca F., et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol 2014, [Epub ahead of print].
14. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
15. Hitsumoto T., Takahashi M., Iizuka T., Shirai K. Relationship between metabolic syndrome and early stage coronary atherosclerosis. J Atheroscler Thromb 2007, 14:294-302.
16. Amar J., Ruidavets J.B., Chamontin B., Drouet L., Ferrieres J. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001, 19:381-387.
17. Schmidt-Trucksass A.S., Grathwohl D., Frey I., et al. Relation of leisure-time physical activity to structural and functional arterial properties of the common carotid artery in male subjects. Atherosclerosis 1999, 145:107-114.
18. Koivistoinen T., Hutri-Kahonen N., Juonala M., et al. Apolipoprotein B is related to arterial pulse wave velocity in young adults: the Cardiovascular Risk in Young Finns Study. Atherosclerosis 2011, 214:220-224.
19. Sierra-Johnson J., Somers V.K., Kuniyoshi F.H., et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006, 98:1369-1373.
20. Zeng Q., Sun X.N., Fan L., Ye P. Correlation of body composition with cardiac function and arterial compliance. Clin Exp Pharmacol Physiol 2008, 35:78-82.
21. Jung C.H., Hwang J.Y., Yu J.H., et al. The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population. Clin Endocrinol (Oxf) 2012, 77:699-706.
22. Morrison J.A., Glueck C.J., Daniels S.R., Horn P.S., Wang P. Determinants of ApoB, ApoA1, and the ApoB/ApoA1 ratio in healthy schoolgirls, prospectively studied from mean ages 10 to 19years: the Cincinnati National Growth and Health Study. Metabolism 2012, 61:1377-1387.
23. Zhong L., Li Q., Jiang Y., et al. The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population. Inflammation 2010, 33:353-358.
24. Olofsson S.O., Wiklund O., Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 2007, 3:491-502.
25. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 1999, 99:2517-2522.
26. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996, 94:273-278.
27. Walldius G., Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004, 255:188-205.
28. Marcovina S., Packard C.J. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006, 259:437-446.
29. Schlitt A., Blankenberg S., Bickel C., et al. Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. Int J Cardiol 2005, 102:477-485.
30. Shah P.K., Kaul S., Nilsson J., Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 2001, 104:2498-2502.
31. Barter P.J., Rye K.A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 2006, 259:447-454.
32. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
33. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991, 325:373-381.
34. Buring J.E., O'Connor G.T., Goldhaber S.Z., et al. Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992, 85:22-29.
35. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
36. Taquet A., Bonithon-Kopp C., Simon A., et al. Relations of cardiovascular risk factors to aortic pulse wave velocity in asymptomatic middle-aged women. Eur J Epidemiol 1993, 9:298-306.
37. Greenland P., Alpert J.S., Beller G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010, 122:e584-e636.
38. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
39. Walldius G., Jungner I., Aastveit A.H., Holme I., Furberg C.D., Sniderman A.D. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004, 42:1355-1363.
40. Lind L. Vasodilation in resistance arteries is related to the apolipoprotein B/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 2007, 190:378-384.
41. Koren S., Shemesh-Bar L., Tirosh A., et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012, 14:561-567.
42. Greve A.M., Olsen M.H., Bella J.N., et al. Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. Am J Hypertens 2012, 25:1017-1023.
43. Hayoz D., Zappe D.H., Meyer M.A., et al. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen. J Clin Hypertens 2012, 14:773-778.